NCT04951921View on ClinicalTrials.gov

Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Cervical Cancer
Interventions
DRUG

Hyperpolarized 13C Pyruvate

Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

Chang Gung Memorial Hospital

OTHER

NCT04951921 - Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy | Biotech Hunter | Biotech Hunter